Anti-GPC3 antibody and cell-penetrating peptide CPP44 dual-ligand modified liposomes for targeted delivery of arsenic trioxide in the treatment of hepatocellular carcinoma.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Anti-GPC3 antibody and cell-penetrating peptide CPP44 dual-ligand modified liposomes for targeted delivery of arsenic trioxide in the treatment of hepatocellular carcinoma.
- Published In:
- Journal of drug targeting, 33(6), 1004-1013 (2025)
- Authors:
- Lin, Congcong, Sun, Jiamin, Yang, Yun, Pan, Xinyao, Sun, Yifan, Sun, Bin, Gan, Chunli
- Database ID:
- RPEP-12164
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12164APA
Lin, Congcong; Sun, Jiamin; Yang, Yun; Pan, Xinyao; Sun, Yifan; Sun, Bin; Gan, Chunli. (2025). Anti-GPC3 antibody and cell-penetrating peptide CPP44 dual-ligand modified liposomes for targeted delivery of arsenic trioxide in the treatment of hepatocellular carcinoma.. Journal of drug targeting, 33(6), 1004-1013. https://doi.org/10.1080/1061186X.2025.2461104
MLA
Lin, Congcong, et al. "Anti-GPC3 antibody and cell-penetrating peptide CPP44 dual-ligand modified liposomes for targeted delivery of arsenic trioxide in the treatment of hepatocellular carcinoma.." Journal of drug targeting, 2025. https://doi.org/10.1080/1061186X.2025.2461104
RethinkPeptides
RethinkPeptides Research Database. "Anti-GPC3 antibody and cell-penetrating peptide CPP44 dual-l..." RPEP-12164. Retrieved from https://rethinkpeptides.com/research/lin-2025-antigpc3-antibody-and-cellpenetrating
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.